NCT04696432 is a Phase 1 clinical trial of Prizloncabtagene autoleucel in Non-Hodgkin's B-cell Lymphoma, sponsored by Tianjin Medical University Cancer Institute and Hospital.

Who is sponsoring NCT04696432?

NCT04696432 is sponsored by Tianjin Medical University Cancer Institute and Hospital.

What drugs are being tested in NCT04696432?

Interventions in NCT04696432: Prizloncabtagene autoleucel.

What condition does NCT04696432 study?

NCT04696432 studies Non-Hodgkin's B-cell Lymphoma.

Is NCT04696432 still recruiting?

NCT04696432 is currently completed. Last updated 28 May 2025.

Last reviewed 2025-05-28 · How we verify

NCT04696432

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of C-CAR039 Treatment in Subjects With r/r NHL SubjectsNon-Hodgkin's Lymphoma

Completed Phase 1 Last updated 28 May 2025

What this trial tests

Phase 1 trial testing Prizloncabtagene autoleucel in Non-Hodgkin's B-cell Lymphoma in 7 participants. Completed in 30 December 2023.

Timeline

27 November 2020

Primary endpoint
31 July 2023

30 December 2023

Quick facts

Lead sponsor	Tianjin Medical University Cancer Institute and Hospital
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	7
Start date	27 November 2020
Primary completion	31 July 2023
Estimated completion	30 December 2023
Sites	1 location across China

Drugs / interventions tested

Prizloncabtagene autoleucel — full drug profile →

Conditions studied

Non-Hodgkin's B-cell Lymphoma — all drugs for Non-Hodgkin's B-cell Lymphoma →

Sponsor

Tianjin Medical University Cancer Institute and Hospital

Who can join

Adults 18 to 70, any sex, with Non-Hodgkin's B-cell Lymphoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a single-center, open-label study to evaluate the safety and efficacy of C-CAR039 in relapsed and/or refractory B-NHL patients.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Next-generation chimeric antigen receptors for T- and natural killer-cell therapies against cancer.
Li Y, Rezvani K, Rafei H. · · 2023 · cited 29× · PMID 37548050 · DOI 10.1111/imr.13255
A phase 1 trial of prizloncabtagene autoleucel, a CD19/CD20 CAR T-cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma.
Yu W, Li P, Zhou L, Yang M, et al · · 2025 · cited 9× · PMID 39813680 · DOI 10.1182/blood.2024026401
Novel CAR T-cell therapies for relapsed/refractory B-cell malignancies: latest updates from 2023 ASH annual meeting.
Zhang W, Li S, Long J, Xie S, et al · · 2024 · cited 3× · PMID 38637863 · DOI 10.1186/s40164-024-00508-4

Verify or expand the search:

Other trials of Prizloncabtagene autoleucel

Trials testing the same drug.

NCT05800977 — A Study of C-CAR039 (Prizloncabtagene Autoleucel) in Patients With Relapsed/Refractory Large B-Cell Lymphoma · Phase 1, PHASE2 · recruiting

Other Tianjin Medical University Cancer Institute and Hospital trials

Trials by the same sponsor.

NCT07493993 — Clinical Study on the Efficacy and Safety of Iparomlimab and Tuvonralimab Injection Combined With Nab-Paclitaxel in Neoa · Phase 2 · not yet recruiting
NCT07515469 — A Prospective, Single-Arm, Exploratory Study of the Safety and Efficacy of Neoadjuvant Treatment With QL1706, an Anti-PD · Phase 2 · not yet recruiting
NCT07475026 — A Study of Neoadjuvant Tislelizumab Plus Lenvatinib in Resectable HCC at High Risk of Recurrence · Phase 3 · not yet recruiting
NCT07510594 — A Phase II Study of Benmelstobart + Anlotinib + Chemotherapy as First-Line Treatment for LCNEC and EP-NEC · Phase 2 · not yet recruiting
NCT07528274 — Microwave Ablation Plus Tislelizumab and Docetaxel in Advanced NSCLC After First-Line Immunotherapy Failure · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04696432 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Tianjin Medical University Cancer Institute and Hospital
Last refreshed: 28 May 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04696432.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing